This site is intended for health professionals only
Saturday 22 July 2017
Share |

Latest News

Positive opinion for first darunavir-based single-tablet regimen for the treatment of HIV-1

Friday 21st July 2017

Janssen-Cilag International NV has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for darunavir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (D/C/F/TAF) (Symtuza), a new once-daily darunavir-based single tablet regimen (STR).

If approved, it will be the only darunavir-based STR indicated for the treatment of human...

Fri, 21 Jul 2017
First investigational targeted biologic in the European Union to receive positive CHMP opinion for atopic dermatitis
Fri, 21 Jul 2017
First and only biologic that selectively targets the IL-17 receptor subunit A in psoriasis
Fri, 21 Jul 2017
Humanised IL-5 antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment
Fri, 14 Jul 2017
Enrollment completed for prospective study (BLADE) to advance second software-based in vitro diagnostic test
Thu, 13 Jul 2017
Cambridge University Hospitals will receive a Most Wired winner’s plaque following the Health Forum and AHA Leadership Summit Most Wired recognition event at the end of July 2017
Thu, 13 Jul 2017
Report finds three quarters of UK MS specialists surveyed agree one in four people with MS surveyed were not even aware that treatments could help delay the onset of disability
Thu, 13 Jul 2017
NICE endorses prescribing across the NHS of Ipsen’s tablet cabozantinib, offering a new therapy option to help battle cancer resistance in advanced renal cell carcinoma in adults (after VEGF-targeted therapy)